AZNCF
Price
$158.20
Change
-$2.45 (-1.53%)
Updated
Aug 28 closing price
Capitalization
248.13B
NVS
Price
$126.38
Change
-$0.09 (-0.07%)
Updated
Aug 29, 04:10 PM (EDT)
Capitalization
244.54B
60 days until earnings call
Interact to see
Advertisement

AZNCF vs NVS

Header iconAZNCF vs NVS Comparison
Open Charts AZNCF vs NVSBanner chart's image
AstraZeneca
Price$158.20
Change-$2.45 (-1.53%)
Volume$602
Capitalization248.13B
Novartis AG
Price$126.38
Change-$0.09 (-0.07%)
Volume$300
Capitalization244.54B
AZNCF vs NVS Comparison Chart in %
Loading...
AZNCF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AZNCF vs. NVS commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZNCF is a Hold and NVS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (AZNCF: $158.20 vs. NVS: $126.47)
Brand notoriety: AZNCF and NVS are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AZNCF: 17% vs. NVS: 42%
Market capitalization -- AZNCF: $248.13B vs. NVS: $244.54B
AZNCF [@Pharmaceuticals: Major] is valued at $248.13B. NVS’s [@Pharmaceuticals: Major] market capitalization is $244.54B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $656.17B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $88.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AZNCF’s FA Score shows that 1 FA rating(s) are green whileNVS’s FA Score has 2 green FA rating(s).

  • AZNCF’s FA Score: 1 green, 4 red.
  • NVS’s FA Score: 2 green, 3 red.
According to our system of comparison, both AZNCF and NVS are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AZNCF’s TA Score shows that 6 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).

  • AZNCF’s TA Score: 6 bullish, 4 bearish.
  • NVS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, AZNCF is a better buy in the short-term than NVS.

Price Growth

AZNCF (@Pharmaceuticals: Major) experienced а +0.25% price change this week, while NVS (@Pharmaceuticals: Major) price change was -0.28% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.84%. For the same industry, the average monthly price growth was +1.29%, and the average quarterly price growth was +11.90%.

Reported Earning Dates

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.84% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AZNCF($248B) and NVS($245B) have the same market capitalization . AZNCF has higher P/E ratio than NVS: AZNCF (29.79) vs NVS (18.44). NVS YTD gains are higher at: 34.645 vs. AZNCF (21.692). NVS has higher annual earnings (EBITDA): 22.7B vs. AZNCF (16.8B). AZNCF (7.11B) and NVS (7B) have equal amount of cash in the bank . NVS (32.6B) and AZNCF (32.8B) have identical debt. AZNCF (56.5B) and NVS (55.2B) have equivalent revenues.
AZNCFNVSAZNCF / NVS
Capitalization248B245B101%
EBITDA16.8B22.7B74%
Gain YTD21.69234.64563%
P/E Ratio29.7918.44162%
Revenue56.5B55.2B102%
Total Cash7.11B7B102%
Total Debt32.8B32.6B101%
FUNDAMENTALS RATINGS
AZNCF vs NVS: Fundamental Ratings
AZNCF
NVS
OUTLOOK RATING
1..100
5225
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
14
Undervalued
PROFIT vs RISK RATING
1..100
4813
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4946
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (14) in the Pharmaceuticals Major industry is in the same range as AZNCF (23) in the null industry. This means that NVS’s stock grew similarly to AZNCF’s over the last 12 months.

NVS's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for AZNCF (48) in the null industry. This means that NVS’s stock grew somewhat faster than AZNCF’s over the last 12 months.

NVS's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as AZNCF (100) in the null industry. This means that NVS’s stock grew similarly to AZNCF’s over the last 12 months.

NVS's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as AZNCF (49) in the null industry. This means that NVS’s stock grew similarly to AZNCF’s over the last 12 months.

NVS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as AZNCF (100) in the null industry. This means that NVS’s stock grew similarly to AZNCF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AZNCFNVS
RSI
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
52%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
49%
Bearish Trend 2 days ago
40%
Momentum
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
55%
MACD
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
55%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
44%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
46%
Advances
ODDS (%)
Bullish Trend 16 days ago
64%
Bullish Trend 3 days ago
49%
Declines
ODDS (%)
Bearish Trend 22 days ago
50%
Bearish Trend 24 days ago
45%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
39%
Aroon
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
31%
View a ticker or compare two or three
Interact to see
Advertisement
AZNCF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FAN18.840.19
+1.02%
First Trust Global Wind Energy ETF
IAUG27.710.09
+0.33%
Innovator Intl Dev Pwr Bffr ETF - Aug
BDGS33.940.07
+0.21%
Bridges Capital Tactical ETF
EUSB43.740.07
+0.16%
iShares ESG Advanced Ttl USD Bd Mrkt ETF
FNDX25.770.02
+0.08%
Schwab Fundamental U.S. Large CompanyETF

AZNCF and

Correlation & Price change

A.I.dvisor indicates that over the last year, AZNCF has been loosely correlated with AZN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AZNCF jumps, then AZN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AZNCF
1D Price
Change %
AZNCF100%
-1.53%
AZN - AZNCF
48%
Loosely correlated
+0.08%
NVS - AZNCF
24%
Poorly correlated
-0.33%
SNY - AZNCF
23%
Poorly correlated
-0.34%
MRK - AZNCF
19%
Poorly correlated
-1.02%
BAYRY - AZNCF
18%
Poorly correlated
-0.97%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
-0.33%
GSK - NVS
68%
Closely correlated
-1.18%
AZN - NVS
61%
Loosely correlated
+0.08%
PFE - NVS
57%
Loosely correlated
-1.87%
JNJ - NVS
54%
Loosely correlated
-0.76%
SNY - NVS
54%
Loosely correlated
-0.34%
More